Can a crocosmia bulb compound tame type 2 diabetes?
NCT ID NCT05826054
First seen Sep 02, 2026 · Last updated Sep 03, 2026 · Updated 1 time
Summary
This early trial tests montbretin A, a compound extracted from crocosmia plant bulbs, in people with type 2 diabetes and in healthy volunteers. The main goal is to find a safe dose and see if it causes fewer stomach side effects than standard diabetes medications. Participants take increasing amounts of montbretin A over two weeks, alongside a standard meal, and undergo blood tests and heart checks. The study focuses on safety and tolerability, not yet on how well it controls blood sugar.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Montbretin A, a purified compound from crocosmia plant bulbs, taken as a dietary supplement
- What this could lead to
- If safe and well-tolerated, montbretin A could become a natural option to help manage blood sugar after meals in type 2 diabetes, with fewer stomach side effects than current drugs.
- What could go wrong
- This is an early, small Phase 1 trial focused on safety, not effectiveness. Montbretin A may cause digestive issues like gas or diarrhea, and it might not prove better than existing treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 1
The first testing in people. Mainly checks safety and dose, usually in a small group.
- Participants
-
15 people
The number who actually took part.
- Started
-
Dec 2023
- Finished
-
Nov 2025
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
19 to 65 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Male or female, age ≤ 65 years; ≥19 years; * Have diagnosed type-2 diabetes mellitus with HbA1C between 6.5% to 11% that is currently managed by diet and no other medications or healthy volunteers defined as not having diagnosis of type-2 diabetes mellitus. * Have routine and normal dietary habits that include three meals a day; * Normal hematological parameters as determined through an in-person screening blood draw including HbA1C \>4.0% in healthy volunteers. * Use of an effective barrier method of birth control throughout the study, surgical sterility, or menopausal for at least 2 years; * In the study team's opinion, capable of understanding the visit schedule requirement and study medication dosing requirements. * Be able to avoid all supplements that affect blood sugar for the duration of the study eg. chromium, bitter melon, thiamine, berberine, alpha-lipoic acid, devil's claw, horse chestnut, fenugreek, ginseng, psyllium, cinnamon, garlic and panax. Exclusion Criteria: * Currently in poor health, as determined by the study doctor * Currently on medication, except vitamins and/or birth control * Not eating three regular meals a day * Current or a history of impairment of gastro-intestinal function, including but not limited to inflammatory bowel disease, colonic ulceration, and/or partial intestinal obstruction * Travelled to a foreign country less than four (4) weeks prior to study entry; * Surgery less than four (4) weeks a prior to study entry; * Pregnant or lactating women; * Planning to participate in other investigational drugs while participating in the study; * Known allergy to study medication or its components (non-medicinal ingredients); and * A history of noncompliance to medical regimens or inability or unwillingness to return for all scheduled visits
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Type 2 diabetes are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
VCHRI Clinical Research Unit
Vancouver, British Columbia, V5Y2S7, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Cost-Effectiveness and implementation of integrated Diabetes-Oral health care in oman: a health belief Model-Based intervention to enhance clinical, behavioral, and exploratory oral microbiome in health system outcomes in type 2 diabetes
- Fibrinogen to albumin ratio (FAR) as a risk factor for type 2 diabetic Nephropathy(DN)
- A digital coach for hunger: can an app retrain appetite to improve diabetes control?
- Can a numbing gel on the feet beat a daily pill for diabetic nerve pain?
- Can a wearable sensor improve blood sugar control in hospitals?
- A handful of almonds a day might fill a nutrition gap in GLP-1 users